Loading…
Loading…
See exactly how PEX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PEX and 80,000+ other tickers.
PEX is the third launch in the Global Private Equity Segment and is a market-cap-selected and -weighted fund, thus offering plain vanilla exposure to investors. The underlying index tracks 30 qualifying listed private equity companies which were screened based on, among other things, greater relative trading volume. Generally, the fund will invest at least 80% of its total assets in component securities of the index, and will primarily invest in common stocks of domestic and foreign companies (including in large part BDCs for US-domiciled companies) of any size.
Filament Health's patented, naturally derived psilocybin drug candidate PEX010 has been shipped to Austin Health in Melbourne for PSI-PHY, an investigator initiated pilot trial of psilocybin-assisted physiotherapy in refractory motor functional neurological disorder, sponsored by The University of Melbourne and funded by the Australian Government's Medical Research Future Fund The study is the first trial of PEX010 in a movement disorder and, to the Company's knowledge, the first anywhere to combine a psychedelic with physiotherapy Toronto, Ontario--(Newsfile Corp. - September 8, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce that its wholly owned subsidiary, Filament Health Corp. ("Filament"), has completed the export of PEX010, its patented, standardized, GMP manufactured botanical psilocybin drug candidate, from Canada to Australia in support of an investigator initiated clinical trial. The trial, known as PSI-PHY, investigates psilocybin-assisted physiotherapy in adults with refractory motor functional neurological disorder ("FND").
Filament Health has completed a further international delivery of its patented, naturally derived psilocybin drug candidate PEX010 to Germany, supporting the first compassionate use program for psilocybin in the European Union The Company believes the continued delivery demonstrates Filament's ability to manufacture, release and supply pharmaceutical-grade botanical psilocybin across international regulatory jurisdictions as new legal access pathways emerge Rhelion intends to leverage Filament's existing GMP manufacturing infrastructure, regulatory experience, intellectual property and international supply capabilities to pursue future commercial supply opportunities as regulated psilocybin markets and patient-access programs develop globally Toronto, Ontario--(Newsfile Corp. - September 3, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce that its wholly owned subsidiary, Filament Health Corp. ("Filament"), has completed a further delivery of PEX010, its patented, standardized, GMP-manufactured botanical psilocybin drug candidate, to the Central Institute of Mental Health ("CIMH") in Mannheim, Germany. Germany's compassionate use program for psilocybin in treatment-resistant depression is the first program of its kind in the European Union and represents an important precedent for regulated patient access to psilocybin outside of clinical trials.
Filament Health's patented, naturally derived psilocybin drug candidate PEX010 will be supplied to an investigator initiated Phase 2a study evaluating a group retreat model of psilocybin therapy in people living with metastatic solid tumors or incurable hematologic malignancies. Toronto, Ontario--(Newsfile Corp. - August 25, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector.
Toronto, Ontario--(Newsfile Corp. - July 16, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010.
Filament Health has commenced the largest production run in its history of its standardized, patented PEX010 botanical psilocybin drug candidate, introducing a new 0.5 mg dose alongside its existing 1, 5 and 25 mg strengths to deliver the widest standardized dosing range available from any natural psilocybin drug candidate, every strength produced using the same proprietary extraction and stabilization methods. Toronto, Ontario--(Newsfile Corp. - July 8, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector.